X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ptk787/zk 222584 (86) 86
humans (62) 62
oncology (55) 55
angiogenesis (47) 47
index medicus (45) 45
animals (30) 30
female (30) 30
vascular endothelial growth factor (27) 27
endothelial growth-factor (26) 26
male (26) 26
bevacizumab (23) 23
cancer (23) 23
colorectal cancer (21) 21
tyrosine kinase inhibitor (20) 20
aged (19) 19
colorectal neoplasms - drug therapy (19) 19
mice (18) 18
middle aged (18) 18
pharmacology & pharmacy (17) 17
vegf (17) 17
colorectal neoplasms - pathology (16) 16
metastasis (16) 16
receptor tyrosine kinases (16) 16
angiogenesis inhibitors - therapeutic use (15) 15
in-vivo (15) 15
receptors, vascular endothelial growth factor - antagonists & inhibitors (15) 15
therapy (15) 15
adult (14) 14
angiogenesis inhibitors - pharmacology (14) 14
expression (14) 14
inhibitor (13) 13
neoplasms - drug therapy (13) 13
oxaliplatin-based chemotherapy (13) 13
phase-iii (13) 13
antineoplastic agents - therapeutic use (12) 12
oxaliplatin (12) 12
protein kinase inhibitors - therapeutic use (12) 12
treatment outcome (12) 12
tumor-growth (12) 12
1st-line treatment (11) 11
aged, 80 and over (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
chemotherapy (11) 11
double-blind (11) 11
fluorouracil (11) 11
neovascularization, pathologic - drug therapy (11) 11
prognosis (11) 11
solid tumors (11) 11
kaplan-meier estimate (10) 10
mice, nude (10) 10
neoplasm metastasis (10) 10
protein kinase inhibitors - pharmacology (10) 10
renal-cell carcinoma (10) 10
cancer research (9) 9
disease-free survival (9) 9
drug therapy (9) 9
research (9) 9
tumor angiogenesis (9) 9
vascular endothelial growth factor a - metabolism (9) 9
vatalanib (9) 9
breast-cancer (8) 8
cell biology (8) 8
colorectal neoplasms - mortality (8) 8
phthalazines - pharmacology (8) 8
pyridines - pharmacology (8) 8
randomized phase-iii (8) 8
research article (8) 8
tumors (8) 8
vascular endothelial growth factor a - antagonists & inhibitors (8) 8
cancer therapies (7) 7
care and treatment (7) 7
cell line, tumor (7) 7
cells (7) 7
combination (7) 7
fluorouracil - administration & dosage (7) 7
growth (7) 7
irinotecan (7) 7
l-lactate dehydrogenase - blood (7) 7
xenograft model antitumor assays (7) 7
antibodies, monoclonal, humanized - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
dose-response relationship, drug (6) 6
enzyme-linked immunosorbent assay (6) 6
hypoxia (6) 6
lactate dehydrogenase (6) 6
leucovorin - administration & dosage (6) 6
monoclonal-antibody (6) 6
neoplasms - pathology (6) 6
nude-mice (6) 6
organoplatinum compounds - administration & dosage (6) 6
potent inhibitor (6) 6
pyridines - therapeutic use (6) 6
sorafenib (6) 6
trial (6) 6
tumor (6) 6
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (6) 6
angiogenesis inhibitors (5) 5
antiangiogenic therapy (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Biology & Therapy, ISSN 1538-4047, 07/2009, Volume 8, Issue 13, pp. 1239 - 1248
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) have been shown to favour tumor growth, suggesting the relevance of pharmaceutical inhibition of MSCs... 
Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Kinase activity | Migration | PTK787/ZK 222584 | Cell cycle | Tube formation | Proliferation | Small molecule tyrosine kinase inhibitor | Mesenchymal stem cells | PROGENITORS | proliferation | MYOCARDIAL-INFARCTION | VIVO | cell cycle | PERIPHERAL-BLOOD | FIBROBLASTS | tube formation | IN-VITRO | ONCOLOGY | kinase activity | mesenchymal stem cells | ENDOTHELIAL-CELLS | migration | EXPRESSION | MARROW STROMAL CELLS | small molecule tyrosine kinase inhibitor | Osteocytes - drug effects | Apoptosis - drug effects | Protein-Tyrosine Kinases - metabolism | Humans | Adipocytes - cytology | Gene Expression Profiling | Adipocytes - drug effects | Dose-Response Relationship, Drug | Protein-Tyrosine Kinases - genetics | Mesenchymal Stem Cells - cytology | Mesenchymal Stem Cells - drug effects | Cell Cycle Proteins - genetics | Bone Marrow Cells - drug effects | Mesenchymal Stem Cells - metabolism | Cell Line | Osteocytes - metabolism | Bone Marrow Cells - cytology | Osteocytes - cytology | Cell Cycle Proteins - metabolism | Cells, Cultured | Cell Adhesion - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Cell Movement - drug effects | Phthalazines - pharmacology | Cell Differentiation - drug effects | Adipocytes - metabolism | HL-60 Cells | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Bone Marrow Cells - metabolism
Journal Article
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 01/2008, Volume 19, Issue 1, pp. 45 - 54
Journal Article
The Veterinary Journal, ISSN 1090-0233, 2007, Volume 173, Issue 3, pp. 564 - 570
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 10, pp. 1341 - 1347
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2477 - 2484
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 07/2007, Volume 34, Issue 7, pp. 419 - 429
Vascular endothelial growth factor (VEGF) and its endothelial cell receptors (VEGFR) have been shown to be involved in the pathogenesis of the contact... 
Langerhans cell migration | skin‐draining lymph nodes | VEGF receptors 1 and 2 | PTK787/ZK 222584 | VEGF | Skin-draining lymph nodes | FACTOR VEGF | DENDRITIC CELLS | LYMPH-NODES | TUMOR ANGIOGENESIS | LANGERHANS CELL-MIGRATION | DERMATOLOGY | IN-VITRO | skin-draining lymph nodes | DELAYED-HYPERSENSITIVITY | T-CELLS | SKIN INFLAMMATION | TRANSGENIC MICE | Ear, External - immunology | Dermatitis, Allergic Contact - immunology | Skin - metabolism | Vascular Endothelial Growth Factor Receptor-1 - physiology | Vascular Endothelial Growth Factor A - metabolism | Cell Migration Inhibition | Dermatitis, Allergic Contact - metabolism | Flow Cytometry | Dermis - blood supply | Langerhans Cells - immunology | Vascular Endothelial Growth Factor Receptor-2 - physiology | Vascular Endothelial Growth Factor A - drug effects | Skin - immunology | Fluorescein-5-isothiocyanate - pharmacology | Vascular Endothelial Growth Factor Receptor-2 - drug effects | Enzyme-Linked Immunosorbent Assay | Laser-Doppler Flowmetry | Lymph Nodes - cytology | Vascular Endothelial Growth Factor Receptor-1 - drug effects | Phthalazines - pharmacology | Animals | Ear, External - blood supply | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Skin - physiopathology | Dermatitis, Allergic Contact - physiopathology | Oxazolone - pharmacology | Antigens, CD | Contact dermatitis | Vascular endothelial growth factor
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue 6, pp. 1560 - 1567
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 68, pp. 113269 - 113281
Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer and disproportionately accounts for the majority of breast cancer related... 
Translational research | Patient derived xenograft | Cell lines | Triple-negative breast cancer | XENOGRAFT MODELS | triple-negative breast cancer | STEM-CELLS | DNA METHYLATION | cell lines | PTK787/ZK 222584 | PHASE-II | patient derived xenograft | CELL BIOLOGY | PARP INHIBITOR ABT-888 | LUNG-CANCER | EPITHELIAL-CELLS | IN-VIVO | DRUG DEVELOPMENT | translational research
Journal Article
Cancer Research, ISSN 0008-5472, 07/2004, Volume 64, Issue 14, pp. 4931 - 4941
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 02/2014, Volume 110, Issue 4, pp. 875 - 881
Background: We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by... 
colorectal cancer | BEVACIZUMAB | PTK787/ZK 222584 | PHASE-III | (FLT)-F-18-PET | MODIFIED FOLFOX-6 | COMBINATION | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | FOLFIRI | ONCOLOGY | ANTIANGIOGENESIS | FOLFOX | OXALIPLATIN-BASED CHEMOTHERAPY | 1ST-LINE THERAPY | axitinib
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2013, Volume 19, Issue 9, pp. 2541 - 2550
Journal Article